Nasdaq:US$17.44 (-0.10) | HKEX:HK$26.92 (-0.76) | AIM:£2.47 (-0.03)
搜索
新聞檔案

通過選擇所需的新聞類型，可以獲得最新的公告或演示文稿。

請使用 「新聞主題」進一步挑選公告類別。

所有公告的全文可以PDF文件的形式下載。 為方便起見，某些公告的部分或全部文字內容以網頁的方式呈現。 如存有任何不一致之處，請以PDF版本為準。

新聞類型
公告及新聞稿
演示文稿
新聞主題
其他業務
監管通知
腫瘤學 / 免疫學
集團
12345678910111213
14
1516171819
找到相關結果： 944
公告及新聞稿, 監管通知 | 2016-06-15

Block Admission
London: Wednesday, June 15, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that an application has been made to the London Stock Exchange plc for a block admission of 1,000,000 ordinary shares, par value of U
閱讀更多
演示文稿, 科學出版物 | 2016-06-03

ASCO 2016: Safety profile and preliminary clinical efficacy of epitinib in EGFRm+ NSCLC
The safety profile of a selective EGFR TKI epitinib (HMPL-813) in patients with advanced solid tumors and preliminary clinical efficacy in EGFRm+ NSCLC patients with brain metastasis Authors: Qing Zhou, Bin Gan, Liwei Yuan, Ye Hua, Yi-Long Wu Ba
閱讀更多
演示文稿, 科學出版物 | 2016-06-03

ASCO 2016: Preliminary results of a phase Ib trial of savolitinib combined with gefitinib in EGFR-mutant lung cancer
Authors: Jin-Ji Yang, Liu Yang, Andrew Farnsworth, Amir Handzel, Tanya Coleman, Shethah Morgan, Yi-Long Wu Background: Savolitinib (AZD6094, volitinib, HMPL-504) is a potent & selective small molecule MET inhibitor. In preclinical models the c
閱讀更多
公告及新聞稿, 監管通知 | 2016-05-31

Total Voting Rights
London: Tuesday, May 31, 2016: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at May 31, 2016, the issued share capital of Chi-Med consisted of 60,649,342 ordinary sha
閱讀更多
公告及新聞稿, 腫瘤學 / 免疫學 | 2016-05-13

和黃醫藥完成呋喹替尼以結直腸癌為適應症的III期臨床試驗的患者入組工作，共招募416名患者
2016年5月13日：和黃醫藥今日宣布呋喹替尼（HMPL-013）以結直腸癌為適應症的III 期臨床試驗“ FRESCO” 順利完成患者入組工作。2012年，中國新發結直腸癌病例約為39萬例，呋喹替尼的這項關
閱讀更多
查看公告 (PDF)
新聞稿, 集團 | 2016-05-04

Chi-Med to Participate in Two Healthcare Investor Conferences in May
London—May 2, 2016—Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) today announced that Chief Executive Officer Christian Hogg will present a corporate overview at two healthcare investor conferences in May. Conference Details: E
閱讀更多
公告及新聞稿, 監管通知 | 2016-04-29

Total Voting Rights
London: Friday, April 29, 2016: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at April 29, 2016, the issued share capital of Chi-Med consisted of 60,639,926 ordinary
閱讀更多
公告及新聞稿, 監管通知 | 2016-04-27

Results of Annual General Meeting
London: Wednesday, April 27, 2016: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that all ordinary resolutions and the special resolution put to its Annual General Meeting ("AGM") held on April 27, 2016 were duly pas
閱讀更多
演示文稿, 科學出版物 | 2016-04-16

AACR 2016: Activity of Savolitinib against MET Ex14 mutations and resistance to METi through decoupling from MYC expression
Abstract (please download the poster for full details) Authors: Evan Barry, Ryan Henry, Alexandra Borodovsky, Elizabeth Maloney, Brendon Ladd, Melanie Frigault, Michael Zinda, Edwin Clark, Alwin Schuller and Celina D’Cruz Alterations in the
閱讀更多
公告及新聞稿, 集團 | 2016-04-13

Hutchison China MediTech Limited Announces Exercise of Overallotment Option
London: Wednesday, April 13, 2016: Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) announces that the underwriters of its offering of American depositary shares (“ADSs”) on the Nasdaq Global Select Market (the “Offering”) have
閱讀更多
公告及新聞稿, 腫瘤學 / 免疫學 | 2016-04-12

Chi-Med initiates first-in-human clinical trial of novel PI3K inhibitor HMPL-689
London: Tuesday, April 12, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated the first-in-human (“FIH”) Phase I cli
閱讀更多
公告及新聞稿, 監管通知 | 2016-03-31

Total Voting Rights
London: Thursday, March 31, 2016: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at March 31, 2016, the issued share capital of Chi-Med consisted of 60,283,118 ordinary
閱讀更多
公告及新聞稿, 監管通知 | 2016-03-29

Director's Shareholding
London: Tuesday, March 29, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM / Nasdaq: HCM) received notification on March 25, 2016 that Mr Christian Hogg, Executive Director and Chief Executive Officer, has purchased 36,600 American Deposi
閱讀更多
公告及新聞稿, 監管通知 | 2016-03-23

Holding(s) in Company
  For filings with the FCA include the annex For filings with issuer exclude the annex TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying is
閱讀更多
公告及新聞稿, 新聞稿, 集團 | 2016-03-22

Closing of U.S. Public Offering of ADSs Raising Approximately US$101 Million on the Nasdaq Stock Market
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTIT
閱讀更多
公告及新聞稿, 監管通知 | 2016-03-21

Director's Shareholding
London: Monday, March 21, 2016: Hutchison China MediTech Limited ("Chi-Med") (AIM / Nasdaq: HCM) received notification on 18 March 2016 that Ms Edith Shih, Non-executive Director, has purchased 40,741 American Depositary Shares ("ADSs", each represen
閱讀更多
公告及新聞稿, 腫瘤學 / 免疫學 | 2016-03-21

Chi-Med initiates sulfatinib Phase III registration study in pancreatic neuroendocrine tumor patients
London: Monday, March 21, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated SANET-p, a Phase III registration trial of s
閱讀更多
公告及新聞稿, 集團 | 2016-03-18

Final Prospectus
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTIT
閱讀更多
公告及新聞稿, 集團 | 2016-03-17

Pricing of U.S. Public Offering of ADSs
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONS
閱讀更多
公告及新聞稿, 新聞報導, 集團 | 2016-03-17

Hutchison China MediTech Limited Announces Pricing of U.S. Public Offering of ADSs
Press Release London: Wednesday, March 16, 2016: Hutchison China MediTech Limited ("Chi Med") (AIM: HCM) announces the pricing of its U.S. public offering of American depositary shares (“ADSs”) (the “Offering”), raising gross proceeds of app
閱讀更多
公告及新聞稿, 集團 | 2016-03-15

2015 Annual Report and Notice of Annual General Meeting
London: Tuesday, March 15, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM:HCM) today announces that its 2015 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy have been posted to shareholders. The
閱讀更多
公告及新聞稿, 集團 | 2016-03-07

Repeat of Announcement of Fifth Public Filing of Registration Statement on Form F-1 and Launch of Potential U.S. Public Offering of ADSs
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTIT
閱讀更多
公告及新聞稿, 集團 | 2016-03-04

Hutchison China MediTech Limited Announces Launch of Potential U.S. Public Offering of ADSs
Press Release London: Friday, 4 March 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) announces that it intends to offer and sell, subject to market and other conditions, approximately $100 million of its ordinary shares in the f
閱讀更多
公告及新聞稿, 集團 | 2016-03-04

Fifth Public Filing of Registration Statement on Form F-1 and Launch of Potential U.S. Public Offering of ADSs
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTIT
閱讀更多
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2016-03-02

和黃醫藥啟動索凡替尼以甲狀腺癌為適應症的II期臨床研究
2016年3月2日：和黃醫藥今日宣布正式啟動索凡替尼（HMPL-012）以局部晚期或放射性碘難治性轉移分化的甲狀腺癌（DTC）或甲狀腺髓樣癌（MTC）為適應症在中國開展的一項開放式II期臨床研究，
閱讀更多
下載新聞稿 (PDF)
公告及新聞稿, 集團 | 2016-03-01

Fourth Public Filing of Registration Statement on Form F-1 for potential Nasdaq Stock Market Listing
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTIT
閱讀更多
公告及新聞稿, 集團 | 2016-03-01

Final Results for the year ended 31 December 2015
Record profit from operations at both Group and Commercial Platform levels Excellent progress on all lead drug candidates – five out of five positive Phase Ib/II outcomes in 2015 Seven drug candidates – 19 active clinical trials – 3 Phase III
閱讀更多
公告及新聞稿, 集團 | 2016-02-11

Third Public Filing of Registration Statement on Form F-1 for potential Nasdaq Stock Market Listing
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTIT
閱讀更多
公告及新聞稿, 監管通知 | 2016-01-29

Notice of Announcement of 2015 Final Results
London: Friday, 29 January 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM:HCM) will be announcing its final results for the year ended 31 December 2015 on Tuesday, 1 March 2016.  An analyst presentation will be held at 9:00 am on the
閱讀更多
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2016-01-15

和黃醫藥在澳洲啟動HMPL-523以血液腫瘤為適應症的I期臨床試驗
2016 年1 月15 日：和黃醫藥今日宣佈在澳洲啟動HMPL-523 以惡性血液腫瘤為適應症的I 期臨床試驗。HMPL-523 是針對B 細胞受體信號通路中的酪氨酸激酶Syk 的新型高選擇性小分子抑製劑。此
閱讀更多
下載新聞稿 (PDF)
公告及新聞稿, 監管通知 | 2015-12-29

Blocklisting Six Monthly Return
London: Tuesday, 29 December 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) announces the following blocklisting six monthly return:   1. Name of applicant: Hutchison China MediTech Limited   2. Name of scheme: Hutc
閱讀更多
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2015-12-18

和黃醫藥啟動索凡替尼以神經內分泌瘤為適應症的III期臨床研究
2015 年12 月18 日：和黃醫藥今日宣布正式啟動索凡替尼（HMPL-012）以非胰腺神經內分泌瘤為適應症的中國III 期臨床研究（SANET-ep）。此次研究的受試者均為非胰腺神經內分泌瘤患者，包括
閱讀更多
下載新聞稿 (PDF)
公告及新聞稿, 其他業務, 新聞稿 | 2015-12-09

US$105 million Shanghai land compensation agreement
Press Release London: Wednesday, 9 December 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Shanghai Hutchison Pharmaceuticals Limited (“SHPL”), its 50:50 joint venture with a subsidiary of Shanghai Pharma
閱讀更多
公告及新聞稿, 腫瘤學 / 免疫學 | 2015-12-08

和黃醫藥啟動呋喹替尼以非小細胞肺癌為適應症的III期臨床試驗
2015 年12 月8 日: 和黃醫藥今日宣布呋喹替尼（HMPL-013）以晚期非鱗狀非小細胞肺癌為適應症的中國III 期臨床試驗（FALUCA）正式啟動。呋喹替尼是一種新型高選擇性抑制血管細胞內皮生長
閱讀更多
查看公告 (PDF)
公告及新聞稿, 集團 | 2015-11-13

Second Public Filing of Registration Statement on Form F‑1 for potential Nasdaq Stock Market Listing
The following includes the text of the Announcement, excluding the appendix. For the complete Announcement, please download the PDF. --- NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEM
閱讀更多
公告及新聞稿, 監管通知 | 2015-11-10

Results of Extraordinary General Meeting
London: Tuesday, 10 November 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that the ordinary resolution and the special resolution put to its Extraordinary General Meeting held on 10 November 2015 (“EGM”) were
閱讀更多
公告及新聞稿, 監管通知 | 2015-11-09

Director's Share Dealing
London: Monday, 9 November 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) hereby makes the following amendments to the "Director's Share Dealing" announcement released on 20 October 2015 subsequent to the notification received from Mr
閱讀更多
演示文稿, 科學出版物 | 2015-11-07

EORTC 2015: Synergistic effect of c-Met inhibitor Savolitinib in combination with a VEGFR inhibitor Fruquintinib in clear cell renal cell carcinoma xenograft models
Abstract (please download the poster for full details): Authors: Yongxin Ren, Shiming Fan, Yunxin Chen, Renxiang Tang, Wei Zhang, Jianxing Tang, Linfang Wang, Dongxia Shi, Hongbo Chen, Min Cheng, Weiguo Qing, Weiguo Su Renal cell carcinoma (RCC
閱讀更多
演示文稿, 科學出版物 | 2015-11-06

EORTC 2015: First-in-human phase I study of selective VEGFR/FGFR dual inhibitor sulfatinib with milled formulation in patients with advanced solid tumors
Abstract (download poster for full details): Authors: Jian-Ming Xu, Lin Shen, Yan Wang, Yu-ling Chen, Ru Jia, Jian Wang, Ke Li, Yang Sai, Jing Li, Chuan Qi, Hua Ye, Su Weiguo Background: Sulfatinib is a highly selective oral small molecule inhi
閱讀更多
公告及新聞稿, 腫瘤學 / 免疫學 | 2015-11-06

和黃醫藥啟動索凡替尼在美國的臨床試驗
2015年11月6日：和黃醫藥今日宣布啟動索凡替尼（HMPL-012）在美國的I期臨床試驗。該藥的美國新藥臨床研究申請於今年遞交並通過，2015年11月4日首位受試者接受給藥治療。此外，和黃醫藥將
閱讀更多
查看公告 (PDF)
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2015-10-30

Sulfatinib clinical results and fruquintinib-savolitinib combination preclinical results to be presented at the 2015 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference
 Press Release London: Friday, 30 October 2015: Hutchison China MediTech Limited (“Chi‑Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, will present further scientific data on sulfa
閱讀更多
公告及新聞稿, 監管通知 | 2015-10-30

Total Voting Rights
London: Friday, 30 October 2015: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) hereby notifies the market that as at 30 October 2015, the issued share capital of Chi-Med consisted of 56,533,118 ordinary shares
閱讀更多
公告及新聞稿, 腫瘤學 / 免疫學 | 2015-10-30

和黃醫藥宣布新型Syk 抑製劑HMPL-523治療免疫疾病的I期臨床試驗取得成功
2015 年10 月30 日: 和黃醫藥（上海）有限公司（簡稱“ 和黃醫藥” ）今日宣布成功完成HMPL ‑ 523 的I 期臨床試驗。HMPL-523 是針對B 細胞受體信號通路中的酪氨酸激酶Syk 的新型高選擇
閱讀更多
查看公告 (PDF)
公告及新聞稿, 腫瘤學 / 免疫學 | 2015-10-23

Proof-of-concept study of fruquintinib in non-small cell lung cancer triggers milestone payment
London: Friday, 23 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, is set to receive a US$10 million milestone payment, in the fourt
閱讀更多
公告及新聞稿, 監管通知 | 2015-10-20

Director's Share Dealing
London: Tuesday, 20 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) received notification on 19 October 2015 that Mr Christopher Nash, Independent Non-executive Director, has: purchased jointly with his spouse 4,512 ordi
閱讀更多
公告及新聞稿, 監管通知 | 2015-10-19

Awards under Long Term Incentive Plan
London: Monday, 19 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) announces that the Remuneration Committee of Chi-Med today granted conditional awards (the “LTIP Awards”) under the Long Term Incentive Plan (the “LTIP
閱讀更多
公告及新聞稿, 新聞稿, 集團 | 2015-10-16

Hutchison China MediTech Limited Files Registration Statement for Potential Nasdaq Stock Market Listing
Press Release London: Friday, 16 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) announces that it has publicly filed today a registration statement on Form F-1 (the "Registration Statement") with the United States Securiti
閱讀更多
公告及新聞稿, 集團 | 2015-10-16

Shareholders' Circular and Notice of Extraordinary General Meeting
London: Friday, 16 October 2015: Hutchison China MediTech Limited ("Chi-Med”) (AIM: HCM) today announces that, following the announcement that it had publicly filed a registration statement on Form F-1 ("Form F-1 Registration Statement") with the U
閱讀更多
公告及新聞稿, 集團 | 2015-10-16

Filing of Registration Statement on Form F-1 for potential Nasdaq Stock Market Listing
The following includes the text of the Announcement but excludes the appendix. For the complete release, please download the PDF. --- NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEM
閱讀更多
公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2015-10-13

Savolitinib completes enrolment for Phase II clinical trial in Papillary Renal Cell Carcinoma
Press Release London: Tuesday, 13 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, and AstraZeneca AB (publ) (“AstraZeneca”) ha
閱讀更多
12345678910111213
14
1516171819